Brokerages expect Astrazeneca PLC (NYSE:AZN) to announce earnings of $0.46 per share for the current quarter, according to Zacks. Three analysts have provided estimates for Astrazeneca PLC’s earnings, with the lowest EPS estimate coming in at $0.38 and the highest estimate coming in at $0.53. Astrazeneca PLC reported earnings of $1.21 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 62%. The business is expected to report its next quarterly earnings results on Thursday, February 1st.
According to Zacks, analysts expect that Astrazeneca PLC will report full year earnings of $1.93 per share for the current year, with EPS estimates ranging from $1.82 to $2.28. For the next fiscal year, analysts expect that the business will post earnings of $1.84 per share, with EPS estimates ranging from $1.67 to $2.09. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Astrazeneca PLC.
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a return on equity of 34.02% and a net margin of 15.90%. Astrazeneca PLC’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 earnings per share.
AZN has been the topic of several recent research reports. BMO Capital Markets initiated coverage on Astrazeneca PLC in a research report on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 price objective on the stock. Sanford C. Bernstein upgraded Astrazeneca PLC from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $30.00 to $39.00 in a research report on Friday, September 22nd. Leerink Swann downgraded Astrazeneca PLC from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $36.00 to $31.00 in a research report on Thursday, July 27th. Natixis upgraded Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. Finally, Argus restated a “buy” rating and issued a $35.00 price objective on shares of Astrazeneca PLC in a research report on Friday, September 1st. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. Astrazeneca PLC currently has a consensus rating of “Hold” and an average price target of $34.20.
Several institutional investors have recently added to or reduced their stakes in AZN. Meeder Asset Management Inc. purchased a new position in shares of Astrazeneca PLC in the 2nd quarter worth about $105,000. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after buying an additional 984 shares in the last quarter. Valeo Financial Advisors LLC acquired a new stake in shares of Astrazeneca PLC in the third quarter valued at about $133,000. Bronfman E.L. Rothschild L.P. grew its stake in shares of Astrazeneca PLC by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after buying an additional 1,769 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its stake in shares of Astrazeneca PLC by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after buying an additional 846 shares in the last quarter. Institutional investors own 14.44% of the company’s stock.
Astrazeneca PLC (AZN) traded up $0.10 during trading on Monday, reaching $33.83. The company’s stock had a trading volume of 1,277,300 shares, compared to its average volume of 4,762,066. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The firm has a market capitalization of $85,400.85, a price-to-earnings ratio of 8.05, a price-to-earnings-growth ratio of 3.19 and a beta of 0.75. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/23/astrazeneca-plc-azn-expected-to-post-earnings-of-0-46-per-share.html.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Get a free copy of the Zacks research report on Astrazeneca PLC (AZN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.